Home » Stocks » BVXV

BiondVax Pharmaceuticals Ltd. (BVXV)

Stock Price: $2.96 USD -0.01 (-0.34%)
Updated Jun 24, 2021 2:39 PM EDT - Market open
Market Cap 42.51M
Revenue (ttm) n/a
Net Income (ttm) -2.69M
Shares Out 14.33M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $2.96
Previous Close $2.97
Change ($) -0.01
Change (%) -0.34%
Day's Open 3.00
Day's Range 2.88 - 3.00
Day's Volume 42,638
52-Week Range 2.35 - 62.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

JERUSALEM, June 23, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

1 day ago - PRNewsWire

JERUSALEM, May 13, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pre...

1 month ago - PRNewsWire

JERUSALEM, March 23, 2021 /PRNewswire/ -- Dear Shareholders, After many years of pharmaceutical leadership positions in the US and Europe, I jumped at the opportunity to return to my roots in Israel to ...

3 months ago - PRNewsWire

JERUSALEM, Feb. 10, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

4 months ago - PRNewsWire

JERUSALEM, Israel, Feb. 2, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for...

4 months ago - PRNewsWire

JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

4 months ago - PRNewsWire

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

4 months ago - PRNewsWire

JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the pr...

4 months ago - PRNewsWire

JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment o...

5 months ago - PRNewsWire

The company reported negative results from a pivotal clinical trial.

8 months ago - The Motley Fool

BlondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was absolutely crushed on Friday after the company reported late-stage results from its flu vaccine study.

8 months ago - 24/7 Wall Street

JERUSALEM, Oct. 23, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, sea...

8 months ago - PRNewsWire

JERUSALEM, Israel, Oct. 2, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Comp...

8 months ago - PRNewsWire

BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company

9 months ago - Seeking Alpha

JERUSALEM, Aug. 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

10 months ago - PRNewsWire

JERUSALEM, July 1, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial o...

11 months ago - PRNewsWire

JERUSALEM, June 30, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza v...

11 months ago - PRNewsWire

JERUSALEM, June 12, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza v...

1 year ago - PRNewsWire

JERUSALEM, June 10, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001...

1 year ago - PRNewsWire

JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $...

1 year ago - PRNewsWire

About BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Industry
Biotechnology
Founded
2003
CEO
Ron Babecoff
Employees
21
Stock Exchange
NASDAQ
Ticker Symbol
BVXV
Full Company Profile

Financial Performance

Financial numbers in millions ILS.
Financial Statements